Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1

Interventions

Cisplatin 76Cetuximab 60pembrolizumab 56Radiotherapy, Intensity-Modulated 37Radiotherapy 33Carboplatin 31Docetaxel 30Fluorouracil 27Nivolumab 26Paclitaxel 20Platinum 10Albumin-Bound Paclitaxel 9Surgical Procedures, Operative 8Radiosurgery 8Radiation 8Erlotinib Hydrochloride 8durvalumab 7Bevacizumab 71,2-diaminocyclohexaneplatinum II citrate 7epacadostat 6Biopsy 6Radiotherapy, Conformal 5Ipilimumab 5Immunoglobulin G 5Gemcitabine 5Capecitabine 5130-nm albumin-bound paclitaxel 5utomilumab 4tremelimumab 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Squamous Cell Carcinoma of Head and Neck × Toll-Like Receptor 1 × Clear all
NCT03083873 2023-10-12

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Iovance Biotherapeutics, Inc.

Phase 2 Completed
64 enrolled 15 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡